ClinicalTrials.gg
CompletedNCT01247350Updated Apr 13, 2018Results posted

A Study of LY3009104(Baricitinib) for Healthy Subjects

A Phase 1 interventional study of LY3009104 and Placebo in Healthy Volunteer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females. Male subjects: Agree to use 2 forms of highly effective methods of with female partners of for the specified duration. Female subjects: Females must not be pregnant, breastfeeding, or at risk to become pregnant during study participation. Female subjects of childbearing potential must test negative for pregnancy at screening and agree to use 2 forms of highly effective methods of birth control, or remain abstinent for the specified duration.
  • Up to third generation Japanese, that is defined as all of the subject's biological grandparents are of exclusive Japanese decent and have been born in Japan.
  • Are between the (BMI) of 18.0 and 30.0 kg/m², inclusive at screening.

Exclusion criteria

Exclusion Criteria:

  • Are subjects who have previously completed or withdrawn from this study or any other study investigating LY3009104, and received the study drug.
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Show evidence of significant active neuropsychiatric disease.
  • Have current or recent history of herpes zoster or simplex in the last 90 days prior to randomization, or history of herpes zoster, such as disseminated herpes zoster involving multiple dermatomes, ocular involvement, including herpes zoster involving the ophthalmic branch of the trigeminal nerve.
  • Have or have a history of rheumatoid arthritis.
  • History of , with the exception of cured basal cell or squamous cell carcinoma of the skin.
  • History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed.
  • Receipt of blood products within 2 months prior to study entry.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    2 mg LY3009104 (Cohort 1)

    2mg administered once on day 1 (single dose)

    Drug: LY3009104

  • Experimental
    5 mg LY3009104 (Cohort 2)

    5mg administered once on day 1 (single dose)

    Drug: LY3009104

  • Experimental
    10 mg LY3009104 (Cohort 3)

    10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)

    Drug: LY3009104

  • Experimental
    14 mg LY3009104 (Cohort 4 )

    14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)

    Drug: LY3009104

  • Placebo comparator
    Placebo

    administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: baricitinib

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Effects

    Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.

    Time frame: Days 1-10 for Cohorts 1 & 2, Days 1-7 for single dose of Cohorts 3 & 4, Days 8-31 for multiple doses

Secondary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104

    Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104

    AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose

  3. Pharmacokinetics: Half-Life(t1/2) of LY3009104

    Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose

  4. Pharmacokinetics: Apparent Volume of Distribution of LY3009104

    Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose

  5. Pharmacokinetics: Apparent Total Body Clearance of LY3009104

    Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose

  6. Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)

    Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.

    Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose

  7. Pharmacokinetics: Renal Excretion of LY3009104

    Percentage of LY3009104 excreted in urine from zero to 24 hours.

    Time frame: Day 1: continuous for 24 hours

07

Results

Posted Apr 13, 2018

Participant flow

Participant flow — Overall Study
Milestone2 mg LY3009104 (Baricitinib)5 mg LY300910410 mg LY300910414 mg LY3009104Placebo
Started66679
Received multiple doses of study drug00665
Completed66568
Not completed00111
Withdrew: Adverse event00100
Withdrew: Withdrawal by subject00010
Withdrew: Entry criteria not met00001

Outcome measures

PrimaryNumber of Participants With Clinically Significant Effects

Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.

Time frame:
Days 1-10 for Cohorts 1 & 2, Days 1-7 for single dose of Cohorts 3 & 4, Days 8-31 for multiple doses
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Effects
Participants2 mg LY3009104 Single Dose5 mg LY3009104 Single Dose10 mg LY3009104 Single Dose14 mg LY3009104 Single DosePlacebo Single Dose10 mg LY3009104 Multiple Dose14 mg LY3009104 Multiple DosePlacebo Multiple Dose
Serious Adverse Events00000000
Nonserious Adverse Events11276542
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of LY3009104

Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · nanomoles/Liter (nmol/L)
Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104
nanomoles/Liter (nmol/L)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Maximum Concentration (Cmax) of LY300910476.1 ± 29220 ± 35327 ± 43410 ± 19319 ± 30439 ± 9
SecondaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104

AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · nanomoles*hour/Liter (nmol*h/L)
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104
nanomoles*hour/Liter (nmol*h/L)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104403 ± 101240 ± 231730 ± 212790 ± 141970 ± 183060 ± 17
SecondaryPharmacokinetics: Half-Life(t1/2) of LY3009104

Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · hour (h)
Pharmacokinetics: Half-Life(t1/2) of LY3009104
hour (h)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Half-Life(t1/2) of LY30091045.19 (3.88 to 6.31)6.82 (5.70 to 7.79)6.43 (4.37 to 9.90)8.48 (6.95 to 10.8)8.57 (7.43 to 9.30)9.41 (7.24 to 13.1)
SecondaryPharmacokinetics: Apparent Volume of Distribution of LY3009104

Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · Liter (L)
Pharmacokinetics: Apparent Volume of Distribution of LY3009104
Liter (L)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Apparent Volume of Distribution of LY300910496.3 ± 1899.4 ± 29138 ± 41150 ± 19169 ± 24167 ± 23
SecondaryPharmacokinetics: Apparent Total Body Clearance of LY3009104

Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose
Reported as:
Geometric mean · Liter/hour (L/h)
Pharmacokinetics: Apparent Total Body Clearance of LY3009104
Liter/hour (L/h)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Apparent Total Body Clearance of LY300910412.9 ± 1110.1 ± 2214.8 ± 2012.2 ± 1713.7 ± 1812.3 ± 17
SecondaryPharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)

Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.

Time frame:
Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose
Reported as:
Median · hour (h)
Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)
hour (h)2 mg LY3009104 Day 15 mg LY3009104 Day 110 mg LY3009104 Day 114 mg LY3009104 Day 110 mg LY3009104 Day 1714 mg LY3009104 Day 17
Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)1.00 (0.50 to 2.00)1.00 (0.50 to 1.00)1.25 (0.50 to 2.00)1.00 (0.50 to 2.10)1.00 (0.50 to 2.00)1.00 (1.00 to 1.00)
SecondaryPharmacokinetics: Renal Excretion of LY3009104

Percentage of LY3009104 excreted in urine from zero to 24 hours.

Time frame:
Day 1: continuous for 24 hours
Reported as:
Geometric mean · percentage of drug
Pharmacokinetics: Renal Excretion of LY3009104
percentage of drug10 mg LY3009104 Day 114 mg LY3009104 Day 1
Pharmacokinetics: Renal Excretion of LY300910475.8 ± 763.6 ± 13

Adverse events

Collected over From starting of the dose to follow-up. Adverse events (AE) for single dose were observed from Day 1 to Day 10±2 days (Cohorts 1&2) or Day 7 (Cohorts 3&4). AE for multiple doses were observed from Day 8 to Day 31±3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 mg LY3009104 - Single Dose—0/6 (0%)1/6 (16.7%)
5 mg LY3009104 - Single Dose—0/6 (0%)1/6 (16.7%)
10 mg LY3009104 - Single Dose—0/6 (0%)2/6 (33.3%)
14 mg LY3009104 - Single Dose—0/7 (0%)7/7 (100%)
Placebo - Single Dose—0/9 (0%)6/9 (66.7%)
10 mg LY3009104 - Multiple Dose—0/6 (0%)5/6 (83.3%)
14 mg LY3009104 - Multiple Dose—0/6 (0%)4/6 (66.7%)
Placebo - Multiple Dose—0/5 (0%)2/5 (40%)
Most frequent other events
Showing 10 of 24
Most frequent other events
Event2 mg LY3009104 - Single Dose5 mg LY3009104 - Single Dose10 mg LY3009104 - Single Dose14 mg LY3009104 - Single DosePlacebo - Single Dose10 mg LY3009104 - Multiple Dose14 mg LY3009104 - Multiple DosePlacebo - Multiple Dose
Neutrophil Count DecreasedInvestigations0/60/60/65/70/91/63/60/5
Vessel Puncture Site HaematomaGeneral disorders1/61/60/63/71/91/60/60/5
FatigueGeneral disorders0/60/60/60/70/92/60/60/5
HeadacheNervous system disorders1/60/61/60/73/92/61/60/5
ExcoriationInjury, poisoning and procedural complications0/60/60/60/72/90/60/60/5
ConstipationGastrointestinal disorders0/60/60/61/70/91/61/61/5
Skin LacerationInjury, poisoning and procedural complications0/60/60/60/70/90/60/61/5
CoughRespiratory, thoracic and mediastinal disorders0/60/60/60/70/90/61/61/5
Nasal CongestionRespiratory, thoracic and mediastinal disorders0/60/60/60/70/91/60/61/5
Throat IrritationRespiratory, thoracic and mediastinal disorders0/60/61/61/70/90/60/61/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)2 mg LY30091045 mg LY300910410 mg LY300910414 mg LY3009104PlaceboTotal
Mean46.3 ± 10.848.0 ± 15.046.7 ± 9.051.1 ± 6.345.1 ± 10.747.4 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)2 mg LY30091045 mg LY300910410 mg LY300910414 mg LY3009104PlaceboTotal
Female3232212
Male3435722
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)2 mg LY30091045 mg LY300910410 mg LY300910414 mg LY3009104PlaceboTotal
Asian6667934
Region of Enrollment
Region of Enrollment(Participants)2 mg LY30091045 mg LY300910410 mg LY300910414 mg LY3009104PlaceboTotal
United States6667934
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 24, 2010
Start
Nov 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Apr 13, 2018
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01247350
Responsible party
Sponsor
First posted
Nov 24, 2010
Start date
Nov 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Apr 13, 2018
Last update
Apr 13, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion